Octapharma wins major tender victory in Norway
LACHEN, Switzerland (20th December 2012) Octapharma was recently awarded an extension of the exclusivity contract for virus inactivated plasma, Octaplas, with all Norwegian hospitals for four more years. Today Norway...
Octapharma hosts symposium at WFH World Congress on meeting the challenges of von Willebrand Disease (VWD) diagnosis and treatment
LACHEN, Switzerland (July, 23, 2012) − Octapharma AG, a leading producer of human proteins for life saving therapies, sponsored the symposium entitled “Meeting the challenges of VWD diagnosis and treatment- Which problems...
Octapharma hosts symposium at WFH World Congress on “Personalizing the Inhibitor Treatment and Prevention” in haemophilia A
LACHEN, Switzerland (July 20th, 2012) – Octapharma AG, a leading producer of human proteins for life saving therapies, proudly sponsored an octanate® symposium entitled “Personalizing the Inhibitor Treatment and Prevention: New...
Octapharma is presenting two scientific symposia on Immune Tolerance Induction in Haemophilia A and von Willebrand Disease at World Federation of Haemophilia World Congress 2012 in Paris
Octapharma AG announces the sponsorship of two scientific symposia during the 2012 World Congress of World Federation of Haemophilia (WFH) held in Paris from July 8 -12, 2012. Octapharma is a leading producer of human proteins...
Octapharma USA expands access to octagam® 5% for participating 340B healthcare facilities
Initiative Focuses on Providing IGIV to Underserved Patients
Octapharma Group releases 2011 Annual Report
2011 has been a successful transitional year for the Octapharma Group. Since octagam® 5% and 10% re-entered all important markets profitability experienced a month-by-month continuous improvement. Re-entry combined with the...